ClinicalTrials.gg
CompletedNCT00606502Updated Mar 5, 2021Results posted

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

A Phase 2 interventional study of Pralatrexate and Erlotinib in Non-small Cell Lung Cancer, sponsored by Spectrum Pharmaceuticals, Inc. Completed at 47 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-05.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
624th of 2,995
201 · median 56
Started
2008
with 113 others
Phase 2
1,078 of 3,368
119 open now
Registered
759th of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 624th largest by enrollment of the 2,995 interventional ones that give a count, is one of 114 that started in 2008, is one of 1,078 in phase 2, and was the 759th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette smokers and who have received at least 1 prior treatment with a platinum drug (cisplatin or carboplatin)

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Stage IIIB/IV non-small cell lung cancer
  • Non-small cell lung cancer
  • NSCLC
  • Lung Cancer
  • Pralatrexate
  • Erlotinib
  • Tarceva
  • PDX
  • Smoking
  • Smoker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed Stage IIIB/ IV non-small cell lung cancer (NSCLC).
  • after treatment with 1 or 2 prior chemotherapy regimens, including at least 1 platinum-based treatment. Patients may have received pemetrexed as 1 of the prior therapies. Patients may not have received therapy as their only prior therapy.
  • Recovered from the toxic effects of prior therapy.
  • (ECOG) performance status of 0 or 1.
  • Smoked ≥ 100 cigarettes in their lifetime, whether a former or current cigarette smoker.
  • Adequate blood, liver and kidney function as defined by laboratory values.
  • Received 1-1.25 mg daily oral folic acid for at least 7 days prior to randomization and 1 mg intramuscular injection of vitamin B12 within 10 weeks prior to randomization.
  • Women of must use medically acceptable and have a negative serum pregnancy test within 14 days prior to randomization. Patients who are for at least 1 year (> 12 months since last menses) or are surgically sterilized do not require this test.
  • Men who are not surgically sterile must use medically safe and effective birth control from the time of study randomization, and agree to continue practicing until at least 90 days after the last administration of study treatment.
  • Accessible for repeat dosing and follow-up.
  • Give written .

Exclusion criteria

Exclusion Criteria:

  • Active concurrent primary (except non-melanoma skin cancer or in situ carcinoma of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years. Patients with other prior malignancies less than 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no evidence of active or recurrent disease.
  • Use of drugs, biologics, or devices within 4 weeks prior to randomization.
  • Previous exposure to pralatrexate or erlotinib.
  • Women who are pregnant or breastfeeding.
  • Congestive Heart Failure Class III/IV according to (NYHA) Functional Classification.
  • Uncontrolled hypertension.
  • (HIV)-positive diagnosis with a of \<100 mm3 or detectable viral load within the past 3 months, and is receiving combination anti-retroviral therapy.
  • Symptomatic central nervous system or lesions for which treatment is required.
  • Major surgery within 2 weeks of study randomization.
  • Receipt of any conventional systemic chemotherapy within 4 weeks (6 weeks for nitrosoureas, mitomycin C), or radiation therapy (RT) within 2 weeks, prior to randomization.
  • Active infection or any serious underlying medical condition, which would impair the ability of the patient to receive protocol treatment.
  • Dementia or significantly altered mental status that would prohibit the understanding and giving of or limit study compliance.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Pralatrexate

    Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).

    Drug: Pralatrexate · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid

  • Active comparator
    Erlotinib

    150 mg orally in tablet form Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.

    Drug: Erlotinib · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid

Interventions

  • Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications. Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications. Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.

    Also known as: FOLOTYN, PDX, (RS)-10-propargyl-10-deazaaminopterin

  • 150 mg orally in tablet form Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.

    Also known as: Tarceva®, Erlotinib hydrochloride

  • Dietary supplementVitamin B12

    1 mg intramuscular injection Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment.

    Also known as: Cyanocobalamin

  • Dietary supplementFolic Acid

    1-1.25 mg orally Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment.

    Also known as: Vitamin B9, Folate, Folacin

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib

    OS was defined as the length of time from randomization until death due to any cause. Patients who were alive at the time of the data cut-off date were censored at the last contact date.

    Time frame: Assessed from date of randomization no less frequently than every 16 weeks for up to 2 years after randomization.

Secondary outcomes

  1. Response Rate (RR) to Treatment of Patients Receiving Pralatrexate vs. Erlotinib

    Number of patients whose tumors responded to Pralatrexate or Erlotinib, using the Response Criteria in Solid Tumors (RECIST).

    Time frame: Assessed every 8 weeks for the first 24 weeks, then every 16 weeks for up to 2 years or until PD or start of subsequent treatment.

  2. Progression-free Survival (PFS) of Patients Receiving Pralatrexate vs. Erlotinib

    PFS was calculated as the number of days from randomization to the date of radiological evidence of PD or death due to any cause.

    Time frame: Assessed every 8 weeks for the first 24 weeks, then every 16 weeks for up to 2 years or until PD or start of subsequent treatment.

  3. Adverse Events of Patients Receiving Pralatrexate vs. Erlotinib

    Time frame: Assessed every 2 weeks while on treatment through safety follow-up visit (35 +/-5 days post-last dose) or early termination visit (at time of withdrawal).

07

Results

Posted Jan 20, 2011
Limitations and caveats
The date of the CRF database cut-off for patients (no further case report form or query data entry) was 24 Jun 2010. As of the CRF data cut-off date, 3 patients, remained on therapy.

Participant flow

Patients were enrolled between January 2008 and June 2009 across 43 study sites in 6 countries.

Randomization
Participant flow — Randomization
MilestonePralatrexateErlotinib
Started100101
Completed97101
Not completed30
Withdrew: Randomized but not treated30
Treatment
Participant flow — Treatment
MilestonePralatrexateErlotinib
Started97101
Completed9798
Not completed03
Withdrew: Treatment ongoing at time of data cutoff03

Outcome measures

PrimaryOverall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib

OS was defined as the length of time from randomization until death due to any cause. Patients who were alive at the time of the data cut-off date were censored at the last contact date.

Time frame:
Assessed from date of randomization no less frequently than every 16 weeks for up to 2 years after randomization.
Reported as:
Median · Months Survival
Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib
Months SurvivalPralatrexateErlotinib
Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib6.7 (5.3 to 9.0)7.0 (3.9 to 7.9)
Statistical analysis
  • Pralatrexate vs Erlotinib · Cox proportional hazard: 0.84 · 95% CI 0.61 to 1.14
SecondaryResponse Rate (RR) to Treatment of Patients Receiving Pralatrexate vs. Erlotinib

Number of patients whose tumors responded to Pralatrexate or Erlotinib, using the Response Criteria in Solid Tumors (RECIST).

Time frame:
Assessed every 8 weeks for the first 24 weeks, then every 16 weeks for up to 2 years or until PD or start of subsequent treatment.
Reported as:
Number · Participants
Response Rate (RR) to Treatment of Patients Receiving Pralatrexate vs. Erlotinib
ParticipantsPralatrexateErlotinib
Complete + Partial Response27
Complete Response (CR)01
Partial Response (PR)26
Stable Disease (SD)3335
Progressive Disease (PD)2936
Disease Control (CR+PR+SD)3542
Unable to Evaluate20
Missing (off or no treatment, not confirmed)3120
SecondaryProgression-free Survival (PFS) of Patients Receiving Pralatrexate vs. Erlotinib

PFS was calculated as the number of days from randomization to the date of radiological evidence of PD or death due to any cause.

Time frame:
Assessed every 8 weeks for the first 24 weeks, then every 16 weeks for up to 2 years or until PD or start of subsequent treatment.
Reported as:
Median · months
Progression-free Survival (PFS) of Patients Receiving Pralatrexate vs. Erlotinib
monthsPralatrexateErlotinib
Progression-free Survival (PFS) of Patients Receiving Pralatrexate vs. Erlotinib3.4 (2.1 to 4.7)2.8 (2.1 to 3.7)
SecondaryAdverse Events of Patients Receiving Pralatrexate vs. Erlotinib
Time frame:
Assessed every 2 weeks while on treatment through safety follow-up visit (35 +/-5 days post-last dose) or early termination visit (at time of withdrawal).
Reported as:
Number · Treated Participants
Adverse Events of Patients Receiving Pralatrexate vs. Erlotinib
Treated ParticipantsPralatrexateErlotinib
At least one AE7577
Grade 3 AEs2518
Grade 4 AEs50
At least one SAE142

Adverse events

Collected over Assessed every 2 weeks while on treatment through safety follow-up visit (35 +/-5 days post-last dose) or early termination visit (at time of withdrawal).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pralatrexate—31/97 (32%)91/97 (93.8%)
Erlotinib—32/101 (31.7%)94/101 (93.1%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventPralatrexateErlotinib
stomatitisGastrointestinal disorders9/970/101
dyspnoeaRespiratory, thoracic and mediastinal disorders5/974/101
respiratory failureRespiratory, thoracic and mediastinal disorders5/971/101
thrombocytopeniaBlood and lymphatic system disorders4/970/101
pyrexiaGeneral disorders2/974/101
dehydrationMetabolism and nutrition disorders1/974/101
sepsisInfections and infestations3/973/101
leukopeniaBlood and lymphatic system disorders3/970/101
abdominal painGastrointestinal disorders0/973/101
pneumoniaInfections and infestations2/973/101
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPralatrexateErlotinib
stomatitisGastrointestinal disorders62/974/101
diarrhoeaGastrointestinal disorders15/9732/101
dermatitis acneiformSkin and subcutaneous tissue disorders4/9728/101
fatigueGeneral disorders25/9716/101
dyspnoeaRespiratory, thoracic and mediastinal disorders12/9722/101
rash maculo-papularSkin and subcutaneous tissue disorders4/9721/101
anaemiaBlood and lymphatic system disorders20/9712/101
anorexiaMetabolism and nutrition disorders16/9719/101
nauseaGastrointestinal disorders12/9717/101
coughRespiratory, thoracic and mediastinal disorders11/9717/101

Baseline characteristics

Age, Customized
Age, Customized(participants)PralatrexateErlotinibTotal
Between 18 and 65 years5860118
>=65 years424183
Age, Continuous
Age, Continuous(years)PralatrexateErlotinibTotal
Median63.0 ± 9.062.0 ± 9.163.0 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)PralatrexateErlotinibTotal
Female313364
Male6968137
Region of Enrollment
Region of Enrollment(participants)PralatrexateErlotinibTotal
United States313768
Czech Republic172037
Hungary171532
India111223
Brazil13922
Argentina11819
08

Study locations

47 sites
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • Hematology Oncology Associates of the Treasure Coast
    Port Saint Lucie, Florida 34952, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Donald Berdeaux
    Great Falls, Montana 59405, United States
  • Summit Medical Group
    Berkeley Heights, New Jersey 07922, United States
  • Hematology and Oncology Associates South Jersey
    Mount Holly, New Jersey 08060, United States
  • New York Oncology Hematology-Oncology Associates, P.C.
    Latham, New York 12110, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • New Bern Cancer Care
    New Bern, North Carolina 28562, United States
  • Signal Point Clinical Research Center
    Middletown, Ohio 45042, United States
  • Baptist Regional Cancer Center
    Knoxville, Tennessee 37920, United States
  • Cancer Therapy and Research Center
    San Antonio, Texas 78229, United States
  • Providence Everett Medical Center
    Everett, Washington 98201, United States
  • Instituto Medico Especializado Alexander Fleming
    Buenos Aires, Cuidad De Buenos Aires C1426ANZ, Argentina
  • Policlinica Privada - Instituto de Medicina Nuclear
    Bahia Blanca, Provincia De Buenos Aires B8000FJI, Argentina
  • Hospital Britanico
    Capital Federal, C1280AEB, Argentina
  • Centro Oncologico Rosario
    Rosario, S2000DSK, Argentina
  • ISIS Clinica Especializada
    Santa Fe, S3000FFU, Argentina
  • CAIPO (Centero Para la Atencion Integral del Paciente Oncologico)
    Tucuman, 4000, Argentina
  • Associação Hospital de Caridade de Ijuí
    Ijui, RS 98700-000, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, RS 90035-903, Brazil
  • Clinionco - Clínica de Oncologia de Porto Alegre
    Porto Alegre, RS 90430-090, Brazil
  • Fundação Pio XII - Hospital do Câncer de Barretos
    Barretos, SP 14780-400, Brazil
  • Biocancer S.A.
    Belo Horizonte, 30150-270, Brazil
  • Instituto do Cancer - Arnaldo Vieira de Carvalho
    Sao Paulo, 01224-010, Brazil
  • Masarykuv onkologicky ustav
    Brno, 656 53, Czechia
  • Palacký University Medical School and Teaching Hospital
    Olomouc, 775 20, Czechia
  • Vitkovicka nemocnice, a. s.
    Ostrava, 703 84, Czechia
  • Fakultni nemocnice na Bulovce
    Praha 8, 180 00, Czechia
  • Fakultni nemocnice v Motole
    Praha, 150 06, Czechia
  • Nemocnice Na Homolce
    Praha, 15003, Czechia
  • National Koranyi TBC and Pulmonology Institute
    Budapest, Pest 1525, Hungary
  • Jósa András Teaching Hospital
    Nyiregyhaza, Szabolcs-Szatmár-Bereg 4412, Hungary
  • Vas County Markusovszky Hospital
    Szombathely, Vas 9700, Hungary
  • Zala County Hospital
    Zalaegerszeg, Zala 8900, Hungary
  • Matrai Allami Gyogyintezet
    Matrahaza, 3233, Hungary
  • Komarom-Esztergom Megyei Onkorm. Szent Borbala Korhaza
    Tatabánya, 2800, Hungary
  • MNJ Radium Hospital and Radium Institute of Oncology and Regional Cancer Centre
    Hyderabaad, Andhra Pradesh 500004, India
  • Indo American Cancer Institute and Research Center
    Hyderabad, Andhra Pradesh 500034, India
  • Kidwai Memorial Institute of Oncology
    Bangalore, Karnataka 560029, India
  • Regional Cancer Center
    Trivandrum, Kerala 695011, India
  • Tata Memorial Hospital
    Mumbai, Maharashtra 400012, India
  • Jehangir Clinical Development Centre Pvt Ltd
    Pune, Mahara 411001, India
  • B.P. Poddar Cancer Institute
    Kolkata, West Bengal 700053, India
  • Dharmashila Cancer Hospital & Research Centre
    New Delhi, 110096, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2008
First posted
Feb 4, 2008
Start
Jan 2008
Primary completionActual
Jun 24, 2010
CompletionActual
Jun 24, 2010
Results first posted
Jan 20, 2011
Last update
Mar 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00606502
Responsible party
Sponsor
First posted
Feb 4, 2008
Start date
Jan 2008
Primary completion
Jun 24, 2010
Completion
Jun 24, 2010
Results posted
Jan 20, 2011
Last update
Mar 5, 2021

Study contacts

Garry Weems, PharmD
study director · Spectrum Pharmaceuticals, Inc
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralatrexate

Start the discussion